Ensitrelvir
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM) [1][2].
Product Specifications
CAS Number
[2647530-73-0]
Product Name Alternative
S-217622
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
SARS-CoV; Virus Protease
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/ensitrelvir.html
Purity
99.66
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
FC1=C(CN2C(N(CC3=NN(C)C=N3)C(N/C2=N\C4=CC5=CN(C)N=C5C=C4Cl)=O)=O)C=C(F)C(F)=C1
Molecular Formula
C22H17ClF3N9O2
Molecular Weight
531.88
Precautions
H302, H315, H319
References & Citations
[1]McKimm-Breschkin JL, et al. COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference. Antiviral Res. 2022;197:105227. |[2]Yuto Unoh, et al. Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. bioRxiv 2022.01.26.477782.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Citation 01
ACS Pharmacol Transl Sci. 2025 Oct 9.|bioRxiv. 2023 Feb 27:2023.02.25.530000.|bioRxiv. 2023 Nov 27.|bioRxiv. 2023 Oct 21.|bioRxiv. 2024 Feb 3.|bioRxiv. 2025 May 30:2025.05.28.656516.|J Biol Chem. 2023 Jul;299 (7) :104886.|Nat Commun. 2023 Feb 25;14 (1) :1076.|Res Sq. 2025 Apr 20.|Res Sq. 2025 Jul 29.|Structure. 2023 Sep 7;31 (9) :1016-1024.e3.|Emerg Microbes Infect. 2025 Dec;14 (1) :2552716.|PNAS Nexus. 2025 Jan 7;4 (1) :pgae578.
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
43274121 3x 1.0µg DNA
SDR42E2 CRISPRa sgRNA lentivector (set of three targets)(Human)
Sign In for Pricing
View Details 
MR201984L4V 200 µL
Cntf (NM_170786) Mouse Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details 